Dexmedetomidine to prevent postoperative delirium
Does perioperative dexmedetomidine prevent delirium, and in whom? Compare dosing and timing, cardiac versus noncardiac surgery, and delirium outcomes alongside bradycardia and hypotension.
Published studies
Open in feedRecent evidence appears first, ordered by publication date. Earlier evidence and papers without precise dates follow separately. Design categories are inferred from PubMed metadata, not evidence grades.
Showing 19 of 19
Recent evidence · past year
-
Delirium in cardiovascular medicine.
AI summary of the abstract, unverified
- This state-of-the-art review covers delirium epidemiology, mechanisms, diagnosis, prevention and treatment across cardiovascular medicine, drawing on interdisciplinary expert input.
- It identifies risk factors such as advanced age, baseline cognitive impairment, cerebrovascular disease, longer operative times, complications and systemic inflammation.
- Non-pharmacological multicomponent prevention is described as strongly supported, while preventive pharmacologic use remains controversial; dexmedetomidine is noted for ICU settings.
- The authors conclude that systematic risk assessment and multimodal prevention should be standard care, with more high-quality studies needed for cardiovascular-specific guidelines.
Original abstract (PubMed)
Delirium is a common yet underrecognized neuropsychiatric syndrome in cardiovascular medicine associated with prolonged hospitalization, increased mortality, and long-term cognitive decline. Patients undergoing interventional or surgical cardiovascular procedures-such as transcatheter aortic valve replacement, surgical aortic valve replacement, coronary artery bypass grafting, or percutaneous coronary interventions-may be particularly vulnerable to its development. Delirium incidence varies widely across cardiovascular procedures, influenced by patient characteristics, procedural invasiveness, and diagnostic methodology. Risk factors include advanced age, baseline cognitive impairment, cerebrovascular disease, extended operative times, perioperative complications, and systemic inflammation. Diagnostic tools such as the Confusion Assessment Method (CAM) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) score are established but underutilized in the diagnosis of delirium. While preventive strategies emphasizing non-pharmacological, multicomponent approaches-such as early mobilization, cognitive stimulation, and sleep hygiene-are supported by strong evidence, preventive use of pharmacologic agents remains controversial. Pharmacologic treatment is reserved for select cases; dexmedetomidine shows benefits in intensive care unit settings, while antipsychotics like quetiapine and risperidone may be used cautiously. Overall, delirium poses a significant clinical challenge in cardiovascular medicine and requires a proactive, interdisciplinary approach. Systematic risk assessment and multimodal preventive strategies should be the standard of care, while pharmacologic treatment should be symptom- and context-specific. Further high-quality studies are needed to inform evidence-based guidelines tailored to cardiovascular populations. The present state-of-the-art review summarizes the current literature on the epidemiology, mechanisms, clinical manifestations, diagnosis, prevention, and treatment of delirium in cardiovascular medicine. By integrating findings and interdisciplinary expert discussions from interventional cardiology, cardiac surgery, and psychiatry, it aims to define the unique vulnerability of this patient population, highlight critical knowledge gaps, and lay the foundation for developing targeted, evidence-based management strategies.
-
Effects of perioperative dexmedetomidine on postoperative delirium in older surgical patients: an updated meta-analysis of randomized controlled trials.
AI summary of the abstract, unverified
- Meta-analysis of 22 RCTs including 4161 older surgical patients under general anesthesia, searched across PubMed, Embase and CENTRAL through July 2026.
- Compared perioperative intravenous dexmedetomidine with control for prevention of postoperative delirium, the primary outcome.
- Dexmedetomidine reduced postoperative delirium (RR 0.56, 95% CI 0.47 to 0.66; P<0.00001; I² 24%) and PONV (RR 0.79, 95% CI 0.62 to 0.99; P=0.04).
- Dexmedetomidine was associated with more intraoperative and postoperative bradycardia and more intraoperative hypotension.
Original abstract (PubMed)
STUDY OBJECTIVE: To evaluate the efficacy of perioperative intravenous dexmedetomidine in preventing postoperative delirium (POD) in older surgical patients. METHODS: A comprehensive literature search was performed across three authoritative databases: PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to July 7, 2026, included all available RCTs evaluating the effect of dexmedetomidine on POD in older surgical patients undergoing general anesthesia. The primary outcome was the incidence of POD. Secondary outcomes encompassed adverse events, including PONV, intraoperative and postoperative bradycardia and intraoperative and postoperative hypotension. The study was registered in the PROSPERO database under the identifier CRD420251001512. RESULTS: A total of 22 RCTs, involving 4161 patients, were included in the analysis. The results show that dexmedetomidine significantly reduced the incidence of POD (RR = 0.56, 95% CI: 0.47 to 0.66; P < 0.00001; I2 = 24%) and reduced PONV (RR = 0.79; 95% CI = 0.62 to 0.99; P = 0.04; I2 = 0%). Furthermore, dexmedetomidine was associated with a higher incidence of intraoperative and postoperative bradycardia as well as intraoperative hypotension. CONCLUSION: This meta-analysis suggests that dexmedetomidine reduces POD and PONV incidence in older surgical patients but increases intraoperative and postoperative bradycardia and intraoperative hypotension.
-
Dexmedetomidine versus propofol for the prevention of postoperative delirium in older adults undergoing regional anaesthesia: A systematic review and meta-analysis.
AI summary of the abstract, unverified
- Systematic review and meta-analysis of five randomized trials, totaling 1613 adults aged 60 or older having surgery under regional anesthesia.
- Compared intraoperative dexmedetomidine with propofol, with delirium assessed using CAM or CAM-ICU.
- Delirium occurred in 7.7% of dexmedetomidine patients versus 16.7% with propofol (RR 0.48, 95% CI 0.36-0.64; P < .001), with low heterogeneity (I² = 13.4%).
- The authors conclude dexmedetomidine is associated with less postoperative delirium, and they rated the certainty of evidence as moderate by GRADE.
Original abstract (PubMed)
Postoperative delirium (POD) is a common complication in older adults undergoing surgery and is associated with adverse clinical outcomes. The choice of intraoperative sedative may influence its occurrence, particularly in the setting of regional anesthesia. A systematic review and meta-analysis of randomized controlled trials comparing dexmedetomidine versus propofol in patients aged ≥60 years was conducted in accordance with PRISMA guidelines, with protocol registration in PROSPERO. The primary outcome was the incidence of POD assessed using validated instruments (CAM or CAM-ICU). Five randomized controlled trials involving a total of 1613 patients were included. The incidence of POD was 7.7% in the dexmedetomidine groups and 16.7% in the propofol groups. The meta-analysis showed a significant reduction in POD with dexmedetomidine (RR 0.48, 95% CI 0.36-0.64; P < .001), with low heterogeneity (I2 = 13.4%). Egger's test did not show significant evidence of publication bias, and trial sequential analysis suggested that the available evidence is sufficient. The certainty of evidence was rated as moderate according to the GRADE approach. In older adults undergoing surgery under regional anesthesia, intraoperative sedation with dexmedetomidine is associated with a lower incidence of POD compared with propofol.
-
Postoperative Delirium Across the Perioperative Pathway: A Structured Narrative Review of Clinical Maturity and Implementation Priorities.
AI summary of the abstract, unverified
- This structured narrative review synthesizes adult postoperative delirium evidence across the perioperative pathway, searching major databases plus ESAIC and ASA resources and reference lists.
- It classifies prevention and therapeutic strategies by clinical maturity, target population, and implementation readiness rather than by pooled effect size.
- The authors report that no single anesthetic technique, processed-EEG target, blood-pressure threshold, cerebral oximetry strategy, or agent consistently prevents delirium across surgical populations.
- Multicomponent non-pharmacological prevention has the most consistent support, dexmedetomidine appears context-dependent, and biomarkers and metabolic targets remain investigational.
Original abstract (PubMed)
Postoperative delirium (POD) is a highly prevalent but frequently underrecognized complication that disproportionately affects frail and older surgical patients. This structured narrative review aims to synthesize contemporary evidence on adult postoperative delirium across the perioperative pathway and to classify major preventive and therapeutic strategies according to clinical maturity, target population, and implementation readiness. A structured literature search of PubMed/MEDLINE, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science Core Collection was performed, supplemented by ClinicalTrials.gov, official ESAIC and ASA resources, reference-list screening, and selected seminal pre-2021 publications. Current evidence supports a multifactorial model in which baseline cognitive and physiological vulnerability interacts with inflammatory, pharmacological, hemodynamic, nociceptive, sleep-related, and environmental stressors. No single anesthetic technique, processed-EEG target, blood-pressure threshold, cerebral oximetry strategy, or pharmacological agent consistently prevents POD across surgical populations. Multicomponent non-pharmacological prevention has the most consistent support, whereas dexmedetomidine and other pharmacological approaches appear context-dependent, and biomarkers and metabolic targets remain investigational. Future progress will depend on standardized delirium ascertainment, better phenotyping, multimodal prediction and prevention strategies, and reliable implementation systems that identify vulnerability early and maintain effective preventive care across transitions.
-
Effect of Preoperative Intranasal Dexmedetomidine on Postoperative Myocardial Injury in Patients Undergoing Coronary Artery Bypass Grafting.
AI summary of the abstract, unverified
- Randomized, double-blind, placebo-controlled single-center trial of 70 patients undergoing on-pump CABG.
- Patients received intranasal dexmedetomidine 1 μg/kg or saline on the night before surgery and again 30 minutes before induction.
- At 24 hours, estimated marginal mean hs-cTnT was 170.29 vs 357.29 ng/L (P < 0.001) favoring dexmedetomidine; CK-MB was also lower.
- Sleep quality scores were higher and postoperative delirium was lower (14.3% vs 37.1%; P = 0.029), but the authors call the findings preliminary.
Original abstract (PubMed)
PURPOSE: To evaluate the effects of preoperative intranasal dexmedetomidine on postoperative myocardial injury biomarkers in patients undergoing on-pump coronary artery bypass grafting (CABG). PATIENTS AND METHODS: In this randomized, double-blind, placebo-controlled trial, 70 patients undergoing on-pump CABG were assigned to receive intranasal dexmedetomidine (1 μg/kg) or saline 30 min before bedtime on the night before surgery and again 30 min before anesthesia induction. The primary outcome was serum high-sensitivity cardiac troponin T (hs-cTnT) at 24 h after surgery. Secondary outcomes included perioperative cardiac biomarkers, preoperative sleep quality, postoperative delirium, and adverse events. RESULTS: For the prespecified primary outcome, hs-cTnT concentrations at 24 h after surgery were significantly lower in the dexmedetomidine group than in the control group (estimated marginal means, 170.29 vs 357.29 ng/L; P < 0.001). Postoperative creatine kinase-MB (CK-MB) concentrations were also lower in the dexmedetomidine group (all P < 0.05). N-terminal pro-B-type natriuretic peptide showed a significant group-by-time interaction (P = 0.030), although between-group differences at individual postoperative time points were not significant. The dexmedetomidine group had higher Leeds Sleep Evaluation Questionnaire scores (62 [60-64] vs 44 [41-50]; P < 0.001) and a lower incidence of postoperative delirium (14.3% vs 37.1%; P = 0.029). Adverse events, mechanical ventilation duration, and intensive care unit (ICU) length of stay did not differ significantly between groups. CONCLUSION: In this single-center trial, two-dose preoperative intranasal dexmedetomidine was associated with lower postoperative hs-cTnT and CK-MB concentrations, better subjective preoperative sleep quality, and a lower observed incidence of postoperative delirium. These findings are preliminary and require confirmation in larger, adequately powered multicenter randomized trials to determine whether the biomarker reductions translate into clinically meaningful cardiovascular benefits. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2500111431.
-
Dose- and endpoint-dependent effects of perioperative esketamine in children: evidence from a targeted review.
AI summary of the abstract, unverified
- This mini review synthesizes a targeted search of pediatric esketamine studies covering analgesia, sedation, propofol injection pain, and emergence delirium or agitation.
- Randomized trials and meta-analyses generally report fewer emergence delirium or agitation events after low intravenous esketamine doses, mostly during sevoflurane adenotonsillectomy.
- Direct dose-comparison evidence in that setting shows increasing benefit up to 0.5 mg/kg intravenously, with no upper efficacy or safety boundary identified.
- The authors conclude that 0.2-0.5 mg/kg IV was the best-studied range for emergence prevention, not a validated therapeutic window, and call for direct dose-timing trials.
Original abstract (PubMed)
Esketamine is being evaluated for several paediatric perioperative indications, including analgesia, procedural sedation, attenuation of propofol injection pain, and prevention of emergence delirium (ED) or emergence agitation (EA). This mini review examines whether evidence identified in a targeted search supports a clinically useful therapeutic window and how dose, timing, route, developmental stage, anaesthetic technique, procedure, co-medication, and outcome definition modify treatment effects. Randomised trials and meta-analyses generally report fewer ED or EA events after low intravenous doses, particularly during sevoflurane anaesthesia for adenotonsillectomy. Direct dose-comparison evidence shows increasing benefit up to 0.5 mg·kg-1 intravenously in that setting, without identifying an upper efficacy or safety boundary. An observational association between esketamine exposure and more ED cannot establish a threshold because treatment selection and perioperative context were not controlled. Effective doses are endpoint-specific: propofol injection pain, procedural sedation, analgesia, and emergence outcomes require different exposure profiles. Intranasal regimens cannot be converted into intravenous equivalents from bioavailability alone, and preclinical neurotoxicity findings do not define a ceiling for a single perioperative dose in children. Among the studies identified, 0.2-0.5 mg·kg-1 was the best-studied intravenous range in selected emergence-prevention settings, not a universal recommendation or validated therapeutic window. Future trials should compare dose and timing directly, incorporate paediatric pharmacokinetic-pharmacodynamic sampling, use endpoint-specific assessment, and extend safety follow-up.
-
Intraoperative Dexmedetomidine and Postoperative Delirium After Head and Neck Cancer Surgery with Free-Flap Reconstruction: A Secondary Analysis of a Randomized Placebo-Controlled Trial.
AI summary of the abstract, unverified
- This delirium-focused secondary analysis of a single-centre, double-blind, placebo-controlled trial enrolled adults having head and neck cancer surgery with free-flap reconstruction.
- Patients received intraoperative dexmedetomidine at 0.3 μg/kg/h until 1 hour before surgery ended, or comparable volumes of saline placebo.
- Delirium over the first 5 postoperative days occurred in 14.9% (7/47) of dexmedetomidine patients versus 34.7% (17/49) of placebo patients (adjusted OR 0.31, 95% CI 0.10-0.92; p = 0.036).
- Pain and early sleep were reported as improved with dexmedetomidine, and haemodynamic adverse events and postoperative complications did not differ significantly between groups.
Original abstract (PubMed)
BACKGROUND: Postoperative delirium is common after major head and neck cancer surgery. We investigated whether intraoperative dexmedetomidine infusion was associated with a lower incidence of postoperative delirium in patients undergoing head and neck cancer surgery requiring free-flap reconstruction. METHODS: This was a delirium-focused secondary analysis of a single-centre, randomized, double-blind, placebo-controlled trial. Adult patients with head and neck cancer scheduled for elective surgery requiring free-flap reconstruction under general anaesthesia were randomly assigned to receive intraoperative dexmedetomidine infusion at 0.3 μg kg-1h-1 until 1 h before the end of surgery; subjects in the placebo group were given comparable volumes of normal saline. The primary outcome was the incidence of delirium during the first 5 postoperative days, assessed once daily using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) or the 3-Minute Diagnostic Confusion Assessment Method (3D-CAM). RESULTS: There was less delirium during the initial 5 postoperative days in patients assigned to dexmedetomidine (14.9%, 7 of 47 patients) than in those given placebo (34.7%, 17 of 49 patients). Dexmedetomidine was associated with lower odds of postoperative delirium after adjustment for age, preoperative Mini-Mental State Examination score, and operative time (adjusted odds ratio 0.31, 95% confidence interval 0.10-0.92; p = 0.036). Postoperative pain and early sleep outcomes were improved by dexmedetomidine. Haemodynamic adverse events and postoperative complications did not differ significantly between groups. CONCLUSION: In patients undergoing head and neck cancer surgery with free-flap reconstruction, intraoperative dexmedetomidine infusion was associated with a lower incidence of postoperative delirium during the first 5 postoperative days, without an apparent increase in perioperative adverse events. CLINICAL TRIAL REGISTRATION: ChiCTR2300067376.
-
Effects of dexmedetomidine on postoperative outcomes in adult non-cardiac surgical patients admitted to the intensive care unit: a systematic review and network meta-analysis of randomized controlled trials.
AI summary of the abstract, unverified
- Systematic review and network meta-analysis of 24 RCTs (22 in the meta-analysis, 2,544 patients) in adults admitted to the ICU after non-cardiac surgery.
- Compared dexmedetomidine with normal saline, midazolam, and propofol as postoperative sedation strategies, with ICU delirium as the primary outcome.
- Dexmedetomidine may reduce delirium versus midazolam (RR 0.11, 95% CI 0.02 to 0.80; very low certainty) and versus normal saline (RR 0.46, 95% CI 0.36 to 0.59; low certainty).
- No differences in extubation time or ICU length of stay across strategies, while bradycardia was probably more likely than with propofol (RR 3.03, 95% CI 1.39-6.25; low certainty).
Original abstract (PubMed)
BACKGROUND: The role of dexmedetomidine in patients admitted to the intensive care unit (ICU) following non-cardiac surgery remains unclear. While dexmedetomidine is widely used for its sedative and potential delirium-sparing properties, its pooled effects on clinically relevant postoperative outcomes in this population are not well established. This systematic review and network meta-analysis evaluated the comparative effectiveness and safety of dexmedetomidine compared with other sedative strategies in postoperative non-cardiac surgical ICU patients. METHODS: We systematically searched PubMed, Cochrane CENTRAL, and Embase from inception to 26 May 2026 for randomised controlled trials (RCTs) comparing postoperative dexmedetomidine with normal saline or other sedatives in adults (≥18 years) admitted to the ICU after non-cardiac surgery. The primary outcome was incidence of delirium during the ICU stay. Secondary outcomes were time to extubation, ICU length of stay, duration of mechanical ventilation, and haemodynamic adverse events. Effect estimates were expressed as relative risks (RRs) or mean differences (MDs) using random-effects models. Risk of bias was assessed using the Cochrane RoB 2 tool, and certainty of evidence was evaluated using the GRADE framework. Interventions were ranked using the surface under the cumulative ranking curve (SUCRA) for each outcome. RESULTS: Twenty-four RCTs involving 2,777 patients were included in the systematic review, of which 22 RCTs involving 2,544 patients contributed to the network meta-analysis. Compared with midazolam (RR 0.11, 95% CI 0.02 to 0.80; very low certainty) and normal saline (RR 0.46, 95% CI 0.36 to 0.59; low certainty), dexmedetomidine may reduce the risk of delirium. Evidence is insufficient to determine whether propofol differs from dexmedetomidine in its effect on delirium. There were no differences in time to extubation, duration of mechanical ventilation, or ICU length of stay across sedative strategies. Dexmedetomidine probably increases the risk of bradycardia compared with propofol (RR 3.03, 95% CI 1.39-6.25; low certainty), but the evidence is insufficient to determine whether the two agents differ in their effects on hypotension. In safety rankings, dexmedetomidine performed least favourably for bradycardia (SUCRA 0.03) and hypotension (SUCRA 0.13). CONCLUSIONS: Dexmedetomidine may reduce postoperative delirium in non-cardiac surgical ICU patients but does not appear to improve ventilatory recovery or ICU length of stay and is associated with higher bradycardia risk. Its principal benefit lies in delirium prevention, supporting an individualised approach to sedative selection.
-
Remimazolam versus dexmedetomidine-based sedation for transcatheter aortic valve implantation: hemodynamic stability and early clinical outcomes.
AI summary of the abstract, unverified
- A retrospective, single-center, propensity-matched cohort of 264 TAVI patients under monitored anesthesia care, 132 per group, was analyzed.
- Remimazolam-based sedation was compared with dexmedetomidine-based sedation for intraprocedural hemodynamic instability.
- Hemodynamic instability was less frequent with remimazolam (53.8% vs. 69.7%; adjusted OR 0.50, 95% CI 0.31-0.82; P = 0.006), driven mainly by fewer vasoactive treatments for hypotension.
- Rescue midazolam use was much lower with remimazolam (1.5% vs. 43.2%), while respiratory events, conversion to general anesthesia, delirium, and 30-day outcomes did not differ.
Original abstract (PubMed)
BACKGROUND: Monitored anesthesia care (MAC) is increasingly used as part of minimalist transcatheter aortic valve implantation (TAVI) pathways, but evidence directly comparing remimazolam- and dexmedetomidine-based MAC with respect to intraprocedural hemodynamic stability and early clinical outcomes remains limited. METHODS: In this retrospective, single-center, propensity score-matched cohort study, 433 patients who underwent TAVI under MAC between January 2021 and May 2026 were identified. After 1:1 propensity score matching, 264 patients were included, with 132 patients in each group. The primary outcome was intraoperative hemodynamic instability, defined as bradycardia requiring anticholinergic treatment or hypotension requiring vasoactive treatment. Other outcomes included rescue midazolam use, respiratory adverse events, and early postoperative clinical outcomes. RESULTS: Remimazolam-based MAC was associated with less intraprocedural hemodynamic instability than dexmedetomidine-based MAC (53.8% vs. 69.7%; adjusted OR, 0.50; 95% CI, 0.31-0.82; P = 0.006), primarily reflecting less frequent vasoactive treatment for hypotension (50.8% vs. 67.4%; adjusted OR, 0.49; 95% CI, 0.30-0.81; P = 0.005). Bradycardia requiring anticholinergic treatment was numerically lower but not statistically significant. Rescue midazolam use was markedly lower with remimazolam (1.5% vs. 43.2%; P < 0.001). Respiratory adverse events, conversion to general anesthesia, postoperative delirium, length of stay, and 30-day clinical outcomes did not differ significantly between groups. CONCLUSIONS: In patients undergoing TAVI under MAC, remimazolam-based sedation was associated with a lower incidence of intraprocedural hemodynamic instability and less frequent rescue midazolam administration than dexmedetomidine sedation, without significant differences in early postoperative clinical outcomes.
-
Precision Sedation for Gastrointestinal Endoscopy in Older Adults: Brain Vulnerability and Recovery.
AI summary of the abstract, unverified
- This narrative-style review addresses sedation for gastrointestinal endoscopy in older adults, who face higher risks of oversedation, hypoxemia, and slow recovery.
- It compares propofol with remimazolam, ciprofol, and dexmedetomidine, and describes monitoring tools such as processed EEG, cerebral oximetry, and capnography.
- The abstract reports no pooled effect sizes or statistics; it argues that propofol's cardiorespiratory depression is dose dependent and that newer agents may offer stability in selected patients.
- The authors conclude that sedation should target the minimum effective depth, and that better short-term cardiopulmonary outcomes should not be assumed to prevent delirium or cognitive decline.
Original abstract (PubMed)
Older adults undergoing gastrointestinal endoscopy are particularly susceptible to oversedation, hypotension, hypoventilation, hypoxemia, and delayed recovery because physiological and cognitive reserve decline with age. Precision sedation provides a practical approach to these problems by tailoring drug selection, dose titration, monitoring, and supportive measures to the individual patient and the requirements of the procedure. Propofol remains widely used because of its rapid onset and predictable recovery, although cardiorespiratory depression remains dose dependent. Remimazolam and ciprofol may offer greater hemodynamic or respiratory stability in selected patients, while dexmedetomidine and combination regimens can reduce exposure to other sedatives but introduce their own limitations. Monitoring with processed electroencephalography, cerebral oximetry, capnography, and routine hemodynamic assessment may help identify excessive sedation or physiological deterioration when findings are interpreted in clinical context. However, improvements in short-term cardiopulmonary outcomes or recovery should not be assumed to prevent postoperative delirium or longer-term cognitive impairment. In older adults, sedation should therefore aim for the minimum effective depth while avoiding excessive drug exposure and promptly correcting respiratory and circulatory disturbances. Further endoscopy-specific studies are needed to determine whether these strategies improve cognitive and functional recovery.
-
Effects of Intranasal Dexmedetomidine on the Night Before Surgery on Postoperative Delirium in Elderly Patients Undergoing Total Knee/Hip Arthroplasty. A Parallel-Arm, Randomized Controlled, Non-Inferiority Trial.
AI summary of the abstract, unverified
- Single-center randomized non-inferiority trial in China with 316 randomized elderly patients (of 535 screened) undergoing elective unilateral total knee or hip arthroplasty.
- Intranasal dexmedetomidine the night before surgery plus IV saline at induction was compared with intranasal saline plus IV dexmedetomidine before induction.
- Delirium within 3 days by CAM occurred in 9.5% vs 7.6%; rate difference 0.02 (95% CI -0.04 to 0.08), reported P<0.001, meeting non-inferiority.
- Authors also reported better sleep the night before surgery, lower preoperative anxiety and pain scores, and fewer adverse events with the intranasal route.
Original abstract (PubMed)
IMPORTANCE: It is crucial to identify preoperative treatment methods that can safely and effectively reduce the incidence of postoperative delirium. OBJECTIVE: To evaluate whether preoperative intranasal dexmedetomidine administration for preventing postoperative delirium is non-inferior to intravenous dexmedetomidine infusion on the operative day before induction for elderly patients undergoing elective knee/hip arthroplasty. DESIGN: This randomized clinical trial was performed at a tertiary hospital in China between January 10, 2025 to August 30, 2025. The follow-up for the last subject was completed on September 6, 2025. SETTING: This was a single center trial. PARTICIPANTS: After qualification screening, 535 patients scheduled for unilateral total knee arthroplasty and total hip arthroplasty under general anesthesia were invited to participate in the study. Ultimately, 316 patients were randomly assigned to the experimental group and the control group. INTERVENTIONS: Patients were randomized to receive intranasal dexmedetomidine (the night before surgery)+intravenous normal saline (before induction) or intranasal normal saline (the night before surgery)+intravenous dexmedetomidine (before induction). MAIN OUTCOMES AND MEASURES: The primary outcome was incidence of postoperative delirium within 3 days after surgery assessed by the Confusion Assessment Method. RESULTS: In the intention-to-treat analysis, the incidence of postoperative delirium within 3 days was 9.5% in experimental group and 7.6% in control group. The rate difference was 0.02 (95% CI: -0.04 to 0.08), meeting the pre-specified non-inferiority criterion (P < 0.001). Patients in experimental group showed significantly improved sleep quality on the night before surgery and lower preoperative anxiety and pain scores. Furthermore, the incidence of adverse events was significantly lower in experimental group. CONCLUSIONS AND RELEVANCE: For elderly patients undergoing major joint arthroplasty, intranasal dexmedetomidine administered the night before surgery is non-inferior to pre-induction intravenous infusion for preventing postoperative delirium. The intranasal route offers additional benefits, including improved preoperative sleep, reduced anxiety, and superior hemodynamic stability.
PubMed 42757376 Publisher (DOI) PubMed types: Equivalence Trial, Journal Article, Randomized Controlled Trial -
Intraoperative Dexmedetomidine Administration to Reduce Emergence Delirium and Narcotic Use in Pediatric Dental Patients.
AI summary of the abstract, unverified
- A quality improvement project with retrospective pre- and post-intervention data compared PACU narcotic use in pediatric dental patients.
- The intervention combined an intraoperative dexmedetomidine bolus with evidence-based education bundles for PACU nurses and CRNAs.
- Narcotic administration in the PACU decreased significantly after the intervention (p < 0.001), with no reported numeric effect size or confidence interval in the abstract.
- The authors conclude the bundle reduced postoperative narcotic use, with no significant change in length of stay.
Original abstract (PubMed)
PURPOSE: This article describes methods of reducing emergence delirium, and subsequently narcotic administration, in the post-anesthesia care unit (PACU) using an intraoperative dexmedetomidine bolus and evidence-based education bundles. DESIGN: Quality improvement (QI) project including retrospective data analysis and evidence-based education bundle intervention. METHODS: Compared the administration of narcotics to pediatric dental patients pre- and post-intervention of intraoperative dexmedetomidine bolus and presentation of evidence-based education bundles to PACU nurses and certified registered nurse anesthetists (CRNAs). FINDINGS: The intervention of evidence-based education bundles and intraoperative dexmedetomidine bolus resulted in significant decrease (p < 0.001) in narcotic administration in the PACU. CONCLUSIONS: Implementation of intraoperative dexmedetomidine and perioperative staff education to prevent and identify emergence delirium for pediatric dental patients resulted in decreased postoperative narcotics administration in the PACU, although no significant change in length of stay.
-
[Multicomponent programs in delirium prevention and delirium management in older adults : Evidence, guideline recommendations and perspectives on delirium-sensitive care].
AI summary of the abstract, unverified
- This is a review of delirium prevention and management evidence and the German S3 guideline in older adults, and it gives no sample size.
- It contrasts nonpharmacological multicomponent programs (HELP, ABCDE(F), CHOPS, AKTIVER) with pharmacological strategies.
- It cites two 2026 meta-analyses reporting a 44% reduction in delirium incidence and shorter duration once delirium was established; drug benefits were inconsistent or limited.
- The authors conclude that the S3 guideline strongly recommends structured, interdisciplinary, person-centered programs, and only dexmedetomidine showed a preventive effect in selected perioperative settings.
Original abstract (PubMed)
Delirium is among the most frequent neuropsychiatric complications in older people. It is associated with functional decline, increased morbidity and mortality, loss of independence, cognitive deterioration and an elevated risk of dementia. Contemporary concepts view delirium as the result of an interplay between predisposing vulnerability factors and acute physiological stressors. Current approaches to delirium prevention and management focus on nonpharmacological multicomponent interventions that combine early mobilization, cognitive reorientation, sleep hygiene, pain management, optimization of nutrition and hydration, delirium screening and family involvement. Programs such as HELP, ABCDE(F) bundle, CHOPS and AKTIVER have shaped the development of evidence-based delirium prevention. The strongest evidence to date derives from two meta-analyses published in 2026. In these studies, nonpharmacological multicomponent programs reduced delirium incidence by 44% and significantly shortened delirium duration in patients with established delirium. In contrast, pharmacological strategies demonstrated inconsistent or limited benefits. Only dexmedetomidine showed a preventive effect in selected perioperative settings. The current German S3 guidelines "Delirium in older age" therefore strongly recommend structured, interdisciplinary and person-centered delirium programs. Future challenges include comprehensive implementation, the development of specialized concepts for high-risk populations, improved cross-sectoral care pathways and the meaningful integration of digital technologies. A delirium-sensitive hospital culture should become a key quality indicator not only in geriatric medicine but also in inpatient care across all clinical disciplines.
-
Effect of Intranasal Dexmedetomidine on the Night Before Surgery for Postoperative Delirium in Older Patients Undergoing Total Hip or Knee Arthroplasty: A Randomized Clinical Trial.
AI summary of the abstract, unverified
- Double-blind, placebo-controlled single-center randomized trial of 232 patients aged 60 or older, ASA 1 to 3, undergoing total hip or knee arthroplasty in China.
- Intranasal dexmedetomidine 100 μg versus normal saline given at 21:00 on the night before surgery.
- Delirium within 3 postoperative days occurred in 10.3% versus 20.7% (relative risk 0.50; 95% CI 0.26-0.95; P=0.030) in the intention-to-treat analysis.
- The authors report improved sleep quality and reduced anxiety and pain, with no severe adverse events or nasal mucosal injury, and suggest sleep improvement may partly explain the delirium reduction.
Original abstract (PubMed)
IMPORTANCE: Postoperative delirium is a common and serious neurocognitive complication in elderly arthroplasty patients, with preoperative poor sleep as a key risk factor. Effective preoperative prevention strategies remain an urgent clinical need. OBJECTIVE: To assess preoperative intranasal dexmedetomidine for preventing postoperative delirium in older adults undergoing hip or knee arthroplasty. DESIGN: This trial was conducted at a single tertiary academic hospital in China from January 10, 2025 to June 10, 2025, with follow-up assessments performed from admission to 7 days after surgery. SETTING: This was a single-center, double-blind, placebo-controlled randomized trial. PARTICIPANTS: 232 elderly patients aged 60 years or older, with American Society of Anesthesiologists (ASA) status 1 to 3, scheduled for total hip or knee arthroplasty under general anesthesia were enrolled and randomized 1:1 after eligibility screening. INTERVENTIONS: Intranasal dexmedetomidine(100 μg total dose) or normal saline, administered at 21:00 on the night before surgery. MAIN OUTCOMES AND MEASURES: The primary outcome was the incidence of postoperative delirium within 3 postoperative days, evaluated by the Confusion Assessment Method. Secondary outcomes included postoperative delirium incidence within 7 days, duration, severity, subtype, perioperative sleep quality, pain, anxiety, quality of recovery, time to ambulation, and adverse events. RESULTS: In the intention-to-treat analysis, the postoperative delirium incidence within 3 days was 10.3% in the dexmedetomidine group and 20.7% in the placebo group [relative risk=0.50; 95% confidence interval (CI)=0.26-0.95; P=0.030]. Intranasal dexmedetomidine could improve sleep quality and reduce preoperative and postoperative anxiety and pain. No severe adverse events or nasal mucosal injuries were observed in either group. CONCLUSION: Intranasal dexmedetomidine on the night before surgery could reduce the incidence of postoperative delirium and improve perioperative sleep quality in older patients undergoing joint arthroplasty. Sleep improvement may partly explain this association, suggesting a potential supportive strategy for delirium prevention. TRIAL REGISTRATION: Chinese Clinical Trial Registry Identifier: ChiCTR2500095414.
-
Efficacy and hemodynamic safety of perioperative dexmedetomidine for the prevention of postoperative delirium in elderly patients undergoing cardiac surgery: an updated systematic review and meta-analysis of randomized controlled trials.
AI summary of the abstract, unverified
- Systematic review and meta-analysis of 15 RCTs including 3,274 older adults undergoing cardiac surgery.
- Perioperative dexmedetomidine was compared with placebo or alternative sedative or analgesic regimens for preventing postoperative delirium.
- Dexmedetomidine lowered postoperative delirium incidence (RR 0.70, 95% CI 0.56 to 0.86, p = 0.001; moderate certainty) but increased reported bradycardia (RR 2.08, 95% CI 1.31 to 3.31).
- The benefit appeared larger against active comparators than placebo or saline. The delirium duration reduction (MD -1.12 days) was low certainty with high heterogeneity.
Original abstract (PubMed)
BACKGROUND: Postoperative delirium (POD) is a common and clinically important complication after cardiac surgery in older adults. We performed an updated systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy and hemodynamic safety of perioperative dexmedetomidine for POD prevention in older adults undergoing cardiac surgery. METHODS: We searched PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials from inception through July 12th, 2026 for RCTs comparing perioperative dexmedetomidine with placebo or alternative sedative /analgesic regimens in elderly patients aged 60 years or older, or in extractable elderly subgroups, undergoing cardiac surgery. Primary outcomes were POD incidence and delirium duration. Secondary outcomes included length of intensive care unit (ICU) stay, length of hospital stay, and the risk of bradycardia and hypotension. RESULTS: Fifteen RCTs involving 3,274 patients were included. Perioperative dexmedetomidine was associated with a lower incidence of POD (Risk Ratio [RR] 0.70, 95% Confidence Interval [CI] 0.56 to 0.86, p = 0.001, I2 = 19%; GRADE: moderate certainty) and shorter duration of delirium among patients with POD (Mean Difference [MD] -1.12 days, 95% CI -1.89 to -0.35, p = 0.01, I2 = 83%; GRADE: low certainty). The apparent benefit was more evident in active-comparator trials than in placebo/saline-controlled trials, but this comparator-dependent pattern should not be interpreted as proof of a uniform neuroprotective effect. However, dexmedetomidine was associated with increased bradycardia (RR 2.08, 95% CI 1.31 to3.31, p = 0.0019, I2 = 0%; GRADE: low certainty). No significant differences were observed for length of ICU stay, length of hospital stay, or hypotension. CONCLUSION: Perioperative dexmedetomidine may reduce POD incidence in selected older cardiac surgery patients, particularly when compared with selected active sedative or analgesic regimens. However, the certainty of evidence was moderate, and the effect was less clear in saline/placebo-controlled trials. Evidence for delirium duration was based on few affected patients, showed substantial heterogeneity, and should not drive the main clinical conclusion. Dexmedetomidine increased reported bradycardia, and clinical use should be individualized with careful hemodynamic monitoring. SYSTEMATIC REVIEW REGISTRATION: https://osf.io/f6nwu.
-
Anaesthetic challenges in a nonagenarian with Parkinson's disease undergoing hip fracture surgery: a case report.
AI summary of the abstract, unverified
- Single case report of one 93-year-old man with Parkinson's disease who underwent cemented hemiarthroplasty for a hip fracture, with a Newari-only language barrier.
- Spinal anaesthesia used 3 mL of 0.5% hyperbaric bupivacaine with 5 µg intrathecal dexmedetomidine, chosen to prolong the block after discussion with the orthopaedic team.
- Intraoperative hypotension (three episodes, treated with mephentermine) and hypoglycaemia (55 mg/dL) occurred, followed by transient delirium and aspiration pneumonia; discharged on postoperative day 10.
- The authors conclude spinal anaesthesia was feasible and emphasise dose optimisation, glycaemic monitoring, continuing dopaminergic therapy, delirium prevention, and dysphagia-safe feeding.
Original abstract (PubMed)
BACKGROUND: Hip fractures in nonagenarian patients with multiple comorbidities present substantial anaesthetic challenges. Parkinson's disease (PD) adds further complexity through motor symptoms, autonomic dysfunction, and the imperative for uninterrupted dopaminergic therapy. CASE PRESENTATION: We report the perioperative anaesthetic management of a 93-year-old male with hypertension, Parkinson's disease, hypothyroidism, and dyslipidaemia who underwent cemented left hemiarthroplasty for a transcervical neck of femur fracture. The case was additionally complicated by a significant language barrier, as the patient was exclusively fluent in Newari. Spinal anaesthesia was administered at L3-L4 using 3 mL of 0.5% hyperbaric bupivacaine with 5 µg intrathecal dexmedetomidine, selected to prolong anaesthesia based on discussion with the orthopaedic team; the rationale and limitations of this dosing strategy are critically appraised in the Discussion. Intraoperatively, the patient developed three episodes of hypotension, likely related to sympathetic blockade and adjuvant effects, managed with incremental doses of mephentermine. An episode of intraoperative hypoglycaemia (blood glucose 55 mg/dL) was promptly corrected with 50% dextrose. Postoperatively, the patient developed transient hypoactive delirium due to temporary interruption of dopaminergic therapy, which resolved after resumption of enteral medications by postoperative day 2. On postoperative day 3, the patient developed aspiration pneumonia after oral feeding was initiated by family members despite a functioning nasogastric tube. The condition was managed with antibiotics and supportive care. The patient subsequently improved and was discharged on postoperative day 10. CONCLUSION: Spinal anaesthesia is feasible in nonagenarians with multiple comorbidities, including Parkinson's disease. This case highlights the need for evidence-based dose optimisation and proactive complication prevention. It further emphasises the importance of low-dose bupivacaine-based spinal anaesthesia in very elderly patients, meticulous perioperative glycaemic monitoring, continuation of dopaminergic therapy, structured delirium prevention strategies, caregiver education, and strict adherence to dysphagia-safe feeding protocols in high-risk geriatric patients.
-
Efficacy of Dexmedetomidine in Preventing Postoperative Delirium in Patients Undergoing Brain Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
AI summary of the abstract, unverified
- Systematic review and meta-analysis of five randomized controlled trials, including 646 adults undergoing brain surgery, with searches run through April 2025.
- Evaluated perioperative dexmedetomidine, given as a loading dose followed by a maintenance infusion, for preventing postoperative delirium.
- The pooled risk ratio was 0.47 (95% CI 0.35-0.63; p < 0.00001), a 53% reduction in delirium risk, with no heterogeneity (I2 = 0%).
- Subgroups showed similar effects across brain tumor and other cranial procedures, adverse events were comparable and mostly mild, and the authors call for multicenter trials.
Original abstract (PubMed)
BACKGROUND: Dexmedetomidine (DEX), a selective alpha-2 adrenergic receptor agonist, is widely used in various surgical settings, including cardiac and general surgeries, for its sedative, analgesic, and neuroprotective properties. Patients undergoing brain surgery are particularly susceptible to postoperative delirium (POD). Given the established benefits of dexmedetomidine in other surgical fields, its potential to mitigate delirium in neurosurgery warrants investigation. METHODS: A systematic search of PubMed, Embase, Scopus, and Cochrane databases was conducted from inception to January 2025 and updated in April 2025, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Risk of bias was assessed, and a meta-analysis was performed using Review Manager 5.4.1. Five randomized controlled trials were included, evaluating the efficacy of DEX in preventing POD in adult patients undergoing brain surgery. RESULTS: A total of 646 patients were enrolled, with DEX administered with a loading dose ranging from 0.5 to 1 μg/kg over 10 min, followed by a maintenance infusion rate of 0.1 to 0.5 μg/kg/h during the surgical procedure. The pooled risk ratio (RR) for POD with DEX was 0.47 (95% confidence interval (CI): 0.35-0.63; p < 0.00001); reflecting a 53% reduction in the risk of postoperative delirium, with no statistical heterogeneity detected (χ2 = 2.09, degrees of freedom (df) = 4, p = 0.72; I2 = 0%). Subgroup analyses showed similar effect estimates across brain tumor and other cranial procedures. Adverse events were comparable between groups and generally mild. CONCLUSIONS: This meta-analysis found that perioperative dexmedetomidine was associated with a significant reduction in postoperative delirium risk in neurosurgical patients. Further multicenter trials are needed to confirm these findings and to refine optimal administration strategies.
-
Dexmedetomidine mitigates postoperative delirium in aged mice via TFEB-linked restoration of microglial lysosomal function and attenuated neuroinflammation.
AI summary of the abstract, unverified
- Preclinical study in aged mice using a laparotomy-with-visceral-manipulation model, comparing Sham, POD, and POD+DEX groups with behavioral, hippocampal, and primary microglia analyses.
- Dexmedetomidine treatment was compared against untreated POD mice, with in vitro work using TFEB knockdown in LPS-stimulated primary microglia.
- DEX improved POD-like behaviors and reduced microglial activation and pro-inflammatory cytokines, with increased lysosomal protein expression and TFEB nuclear translocation; no effect sizes or p values are reported in the abstract.
- The authors conclude that TFEB activation may restore microglial lysosomal function and that enhancing lysosomal function could be a potential POD target; DEX also inhibited NLRP3 signaling, which TFEB knockdown substantially attenuated.
Original abstract (PubMed)
BACKGROUND: Postoperative delirium (POD) is a serious complication in elderly patients. Dexmedetomidine (DEX) can reduce POD incidence, but its neuroprotective mechanisms are unclear. This study investigated whether DEX alleviates POD-like phenotypes and whether hippocampal transcription factor EB (TFEB) contributes to this effect, with a focus on microglial lysosomal function. METHODS: An aged mouse POD model was established via laparotomy with visceral manipulation. Mice were assigned to Sham, POD, and POD+DEX groups. Behavioral tests assessed cognitive and affective functions. Hippocampal tissues were analyzed for neuroinflammation and lysosomal markers. Primary microglia were isolated for in vitro studies involving TFEB knockdown. RESULTS: DEX treatment significantly ameliorated POD-like behaviors and reduced hippocampal microglial activation and pro-inflammatory cytokine levels. DEX treatment was associated with increased lysosomal protein expression and promoted TFEB nuclear translocation in microglia, correlating with enhanced lysosomal gene transcription. In vitro, DEX increased lysosomal acidity and improved functional readouts in LPS-stimulated microglia in a TFEB-dependent manner, suggesting partial recovery of lysosome-dependent clearance. DEX also inhibited the NLRP3 inflammasome pathway, an effect substantially attenuated by TFEB knockdown. Mechanistically, DEX-mediated TFEB activation was associated with reduced mTOR activity. CONCLUSION: DEX mitigates POD-like phenotypes in aged mice, with evidence that TFEB activation in the hippocampus contributes to restoration of lysosomal function and attenuation of neuroinflammation. Microglia appear to be a key cellular compartment in this process. These findings suggest that enhancing lysosomal function may represent a potential target for POD.
-
Effects of Fixed-Dose Postoperative Dexmedetomidine on Delirium and Early Clinical Outcomes After Cardiovascular Surgery: A Retrospective Cohort Study of 408 Patients.
AI summary of the abstract, unverified
- Single-center retrospective cohort of 408 adults undergoing elective cardiovascular surgery (2022–2023), comparing a fixed postoperative dexmedetomidine infusion (n = 188) with no dexmedetomidine (n = 220).
- Exposure was a 24-hour infusion at 0.2 μg/kg/h versus no postoperative dexmedetomidine, with delirium assessed by CAM-ICU at 6 and 24 hours.
- Delirium was less frequent with dexmedetomidine at 6 hours (2.1% vs 7.0%, p = 0.032) and 24 hours (0.5% vs 3.6%, p = 0.042); adjusted OR at 6 hours was 0.25 (95% CI 0.07–0.88).
- Dexmedetomidine was also linked to shorter extubation time (6.85 ± 1.49 vs 9.47 ± 5.61 hours, p < 0.001) and similar adverse events and mortality, though the authors call for prospective confirmation.
Original abstract (PubMed)
OBJECTIVES: Postoperative delirium (POD) is a frequent and serious complication after cardiovascular surgery and is associated with impaired recovery and worse clinical outcomes. Dexmedetomidine has been suggested to reduce delirium risk; however, evidence from real-world cardiac surgery cohorts remains inconsistent. This study evaluated the association between a fixed-dose postoperative dexmedetomidine infusion and delirium incidence, sedation depth, and early clinical outcomes. DESIGN: Single-center retrospective cohort study. SETTING: Tertiary cardiovascular surgery center. PARTICIPANTS: A total of 408 adult patients undergoing elective cardiovascular surgery between January 2022 and December 2023. INTERVENTIONS: Patients received either a fixed-dose dexmedetomidine infusion (0.2 μg/kg/h for 24 hours, n = 188) or no dexmedetomidine (control group, n = 220) in the postoperative period. MEASUREMENTS AND MAIN RESULTS: POD was assessed using the Confusion Assessment Method for the ICU at 6 and 24 hours, and sedation depth was assessed using the Richmond Agitation-Sedation Scale. Dexmedetomidine use was associated with a lower incidence of POD at 6 hours (2.1% v 7.0%, p = 0.032) and 24 hours (0.5% v 3.6%, p = 0.042). Multivariable logistic regression identified dexmedetomidine as an independent factor associated with reduced delirium risk at 6 hours (adjusted odds ratio, 0.25; 95% confidence interval, 0.07-0.88). In addition, patients receiving dexmedetomidine demonstrated deeper and more stable sedation profiles and shorter extubation times (6.85 ± 1.49 hours v 9.47 ± 5.61 hours, p < 0.001), with reduced postoperative analgesic requirements. Hemodynamic adverse events, major complications, and early and 30-day mortality rates were similar between groups. CONCLUSIONS: In this retrospective cohort study, fixed low-dose dexmedetomidine infusion after cardiovascular surgery was associated with a lower observed incidence of early POD, improved sedation profiles, faster extubation times, and reduced analgesic requirements without increased adverse events. These findings suggest that dexmedetomidine may be associated with improved early postoperative recovery in selected cardiac surgery patients. Prospective studies are needed to confirm these findings and further clarify the role of dexmedetomidine in perioperative care.
Earlier evidence / dates not confirmed
Includes older studies, year-only dates, and future-dated records. Inclusion does not imply landmark status.
- No matching papers in this section.
Ongoing registrations
From ClinicalTrials.govRegistrations, not results. These registry entries describe ongoing studies, not their findings. They are not counted as published evidence above; check linked records for updates and associated publications.
No registered ongoing trials found.